A recent study by Feng et al. suggested that a vaccine efficacy of 80% against symptomatic infection with majority SARS‐CoV‐2 Alpha variant was achieved with anti‐S1 IgG antibody levels of ≥264 BAU/ml whereas levels of ≥29 BAU/ml conferred 50% protection.30 Here, PSMD1 is linked to infection.